Soleno Therapeutics, Inc. (SLNO) completed its transition to a commercial-stage company following the March 2025 FDA approval of VYKAT XR, resulting in profitability in Q3 2025. The company operates as a single segment solely focused on this product.
Q3 2025 Financial Highlights: For the three months ended September 30, 2025, the company reported $66.0 million in product revenue and achieved a Net Income of $26.0 million, a significant turnaround from a $76.6 million loss year-over-year. Operating income was $22.1 million, and Basic EPS was $0.49.
Nine-Month Performance: For the
...